Cerenovus, Part of DePuy Synthes Products, Inc.
9
1
1
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
33.3%
3 terminated/withdrawn out of 9 trials
57.1%
-29.4% vs industry average
0%
0 trials in Phase 3/4
75%
3 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
MMA Embolization for Refractory Chronic Migraine
Role: lead
Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA
Role: lead
A Study to Look at Performance of MICRUSFRAME and GALAXY Coils for the Treatment of Intracranial Aneurysms
Role: lead
Safety, Performance of CEREGLIDE 92 Intermediate Catheter in Treatment of Acute Ischemic Stroke
Role: lead
CERENOVUS Neurothrombectomy Devices Registry
Role: lead
Prospective Evaluation to Characterize the Real-World Performance of the EMBOVAC Aspiration Catheter
Role: lead
ARCHIMEDES Compassionate Use Supplement
Role: lead
Study to Evaluate the Safety and Effectiveness of the CODMAN ENTERPRISE® Vascular Reconstruction Device
Role: lead
Post-Market Clinical Follow-Up Study to Confirm Clinical Performance and Safety of the Codman Enterprise® 2 Vascular Reconstruction Device in the Endovascular Treatment of Intracranial Aneurysms
Role: lead
All 9 trials loaded